Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience.

Respiratory medicine - 1 Oct 2017

Dagan Adi, Cohen-Cymberknoh Malena, Shteinberg Michal, Levine Hagit, Vilozni Daphna, Bezalel Yael, Bar Aluma Bat-El, Sarouk Ifat, Ashkenazi Moshe, Lavie Moran, Tsabari Reuven, Blau Hannah, Kerem Eitan, Bentur Lea, Efrati Ori, Livnat Galit

Abstract excerpt

BACKGROUND: Ivacaftor is a drug that increases the probability of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel remaining open. Information about the efficacy of ivacaftor in patients carrying the rare p.Ser549Arg (S549R) CFTR mutation is sparse. AIM: Efficacy of ivacaftor treatment in patients carrying the p.Ser549Arg (S549R) CFTR mutation. METHODS: Data obtained from CF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Chloride Channel Agonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Forced Expiratory Volume

Share to Glucose Tolerance Test

Share to Israel

Share to Quinolones

Share to Vital Capacity

Source

Identifiers

PMID: 28947035
DOI: 10.1016/j.rmed.2017.08.026

Genes

CFTR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience.PMID 28947035Read ↗

Normalization of sweat chloride concentration and clinical improvement with ivacaftor in a patient with cystic fibrosis with mutation S549N.Semantic proximity Read ↗

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.Semantic proximity Read ↗

Ivacaftor in a young boy with the rare gating mutation S549R--use of lung clearance index to track progress: a case report.Semantic proximity Read ↗

Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.Semantic proximity Read ↗

Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR GenotypeSemantic proximity Read ↗

Ivacaftor for the treatment of cystic fibrosis in children under six years of age.Semantic proximity Read ↗

Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.Semantic proximity Read ↗

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.Semantic proximity Read ↗

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.Semantic proximity Read ↗

Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.Semantic proximity Read ↗

The Role of Ivacaftor in Severe Cystic Fibrosis in a Patient With the R117H Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.